PRLD - Latest News

Prelude Therapeutics Incorporated (PRLD), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $202.7M. Beta to the broader market is 0.96.

The article list below shows the most recent PRLD headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent PRLD Headlines

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

globenewswire.com - Oct 13, 2026

Combination cohorts are part of Prelude's Phase 1 trial evaluating PRT13722 in patients with HR+/HER2- breast cancer, on track to initiate enrollment

Head to Head Review: Surrozen (NASDAQ:SRZN) and Prelude Therapeutics (NASDAQ:PRLD)

defenseworld.net - Oct 12, 2026

Prelude Therapeutics (NASDAQ: PRLD - Get Free Report) and Surrozen (NASDAQ: SRZN - Get Free Report) are both small-cap healthcare companies, but which

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock Rated “Moderate Buy” by Sell-Side Analysts

defenseworld.net - Oct 1, 2026

Shares of Prelude Therapeutics Incorporated (NASDAQ: PRLD - Get Free Report) have been assigned an average rating of "Moderate Buy" from the six broke

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

globenewswire.com - Sep 11, 2026

WILMINGTON, Del. , Sept.

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

globenewswire.com - Sep 10, 2026

WILMINGTON, Del. , Sept.

How News Affects PRLD Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PRLD's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked PRLD news questions

What is the latest PRLD news headline?

The most recent PRLD headline (Oct 13, 2026) is "Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the PRLD news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What PRLD news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual PRLD options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.